Acumen Pharmaceuticals, Inc.
$2.84
▲
5.88%
2026-04-21 05:01:00
acumenpharm.com
NMS: ABOS
Explore Acumen Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$203.64 M
Current Price
$2.84
52W High / Low
$3.6 / $0.85
Stock P/E
—
Book Value
$1.16
Dividend Yield
—
ROCE
-133.4%
ROE
-96.2%
Face Value
—
EPS
$-2
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
60
Beta
0.34
Debt / Equity
44.46
Current Ratio
4.07
Quick Ratio
4.07
Forward P/E
-1.77
Price / Sales
—
Enterprise Value
$92.81 M
EV / EBITDA
-0.75
EV / Revenue
—
Rating
Strong Buy
Target Price
$7.4
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Compugen Ltd. | $2.88 | 7.61 | $269 M | — | 23.38% | 44.84% | $2.94 / $1.23 | $1.09 |
| 2. | Zevra Therapeutics, Inc. | $10.78 | 7.23 | $601.51 M | — | -1.72% | 85.66% | $13.16 / $6.85 | $2.72 |
| 3. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 4. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 5. | NeuroSense Therapeutics Ltd. | $0.71 | — | $25.1 M | — | -383.35% | -21.75% | $2.6 / $0.63 | $-0.05 |
| 6. | Jupiter Neurosciences, Inc. | $0.46 | — | $15.86 M | — | -73.72% | -7.39% | $3.33 / $0.31 | $0 |
| 7. | MiMedx Group, Inc. | $3.25 | 10.44 | $507.35 M | — | 22.95% | 21.61% | $7.99 / $3.31 | $1.73 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -25.2 M | -26.51 M | -41.75 M | -30.37 M | -39.6 M | — |
| Net Profit | -25.14 M | -26.45 M | -40.95 M | -28.8 M | -37.15 M | — |
| EPS in Rs | -0.35 | -0.37 | -0.57 | -0.4 | -0.51 | -0.5 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -123.83 M | -114.02 M | -61.14 M | -45.24 M |
| Net Profit | -121.33 M | -102.33 M | -52.37 M | -42.86 M |
| EPS in Rs | -1.68 | -1.42 | -0.73 | -0.59 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 122.83 M | 238.99 M | 310.12 M | 196.59 M |
| Total Liabilities | 52.4 M | 57.18 M | 43.15 M | 7.81 M |
| Equity | 70.43 M | 181.82 M | 266.97 M | 188.78 M |
| Current Assets | 122.25 M | 178.31 M | 246.62 M | 180.33 M |
| Current Liabilities | 30.01 M | 27.61 M | 12.97 M | 7.81 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -115.54 M | -86.22 M | -43.06 M | -35.15 M |
| Investing CF | 133.93 M | 48.03 M | -171.67 M | 39.19 M |
| Financing CF | -0.03 M | 6.93 M | 151.75 M | 3.91 M |
| Free CF | -115.63 M | -86.23 M | -43.09 M | -35.31 M |
| Capex | -0.09 M | -0.02 M | -0.02 M | -0.16 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -95.39% | -22.2% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.